4//SEC Filing
Stanker James H 4
Accession 0000897069-24-001613
CIK 0001533743other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 5:31 PM ET
Size
17.3 KB
Accession
0000897069-24-001613
Insider Transaction Report
Form 4
Stanker James H
Chief Financial Officer
Transactions
- Award
Restricted Stock Units
2024-06-28+385→ 29,547 totalExercise: $0.00→ Common Stock (385 underlying) - Award
Restricted Stock Units
2024-06-28+2,307→ 28,777 totalExercise: $0.00→ Common Stock (2,307 underlying) - Award
Restricted Stock Units
2024-06-28+385→ 29,162 totalExercise: $0.00→ Common Stock (385 underlying) - Exercise/Conversion
Common Stock
2024-04-05+1,675→ 6,638 total - Tax Payment
Common Stock
2024-04-05$2.79/sh−518$1,445→ 6,120 total - Tax Payment
Common Stock
2024-07-10$1.71/sh−282$482→ 6,482 total - Exercise/Conversion
Common Stock
2024-07-10+644→ 6,764 total - Award
Restricted Stock Units
2024-06-28+3,077→ 26,470 totalExercise: $0.00→ Common Stock (3,077 underlying)
Footnotes (4)
- [F1]Distribution of vested restricted shares.
- [F2]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
- [F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
- [F4]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.
Documents
Issuer
Processa Pharmaceuticals, Inc.
CIK 0001533743
Entity typeother
Related Parties
1- filerCIK 0001681718
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 5:31 PM ET
- Size
- 17.3 KB